Across the Industry Brief – Issue 33
Democrats have taken control of both the House and Senate, signaling a significant shift in federal AI policy toward binding oversight. This change comes as the White House finalizes a biosecurity policy aimed at preventing AI-enabled biological weapons, while the EU maintains its regulatory timeline for the AI Act. Meanwhile, a $3 trillion market rout has impacted Anthropic’s IPO valuation, highlighting the sensitivity of frontier-lab valuations to regulatory and political developments. As organizations brace for a new era of oversight and compliance, the landscape for AI regulation is evolving rapidly. Read more to understand the implications for your organization.